Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
Sodium glucose cotransporter-2 (SGLT-2) inhibitors have been widespread in patients with heart failure; however, there is little information regarding its feasibility and safety among patients after the Fontan procedure. We presented five adults after the Fontan procedure who were treated with SGLT-...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2022/5243594 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568168046919680 |
|---|---|
| author | Jun Muneuchi Yuichiro Sugitani Masaru Kobayashi Hiroki Ezaki Hiromu Yamada Mamie Watanabe |
| author_facet | Jun Muneuchi Yuichiro Sugitani Masaru Kobayashi Hiroki Ezaki Hiromu Yamada Mamie Watanabe |
| author_sort | Jun Muneuchi |
| collection | DOAJ |
| description | Sodium glucose cotransporter-2 (SGLT-2) inhibitors have been widespread in patients with heart failure; however, there is little information regarding its feasibility and safety among patients after the Fontan procedure. We presented five adults after the Fontan procedure who were treated with SGLT-2 inhibitors. All patients reduced oedema and/or pleural effusion despite other conjunct medications were ineffective. Although we did not measure the urine volume in all patients, all patients themselves reported an increase in urinary output after the administration of a SGLT-2 inhibitor. In addition, administration of a SGLT-2 inhibitor resulted in weight loss (4/5), an increase in systemic oxygen saturation (4/5), an increase in serum albumin level (4/5), an increase in estimated glomerular filtration ratio (4/5), and a decrease in plasma brain natriuretic peptide level (4/5). Our case series supported the feasibility and safety of SGLT-2 inhibitors in patients with Fontan circulatory failure, although the exact changes in urinary output were unknown in all patients. Further investigation will be required to explore a diuretic effect by SGLT-2 in patients after the Fontan procedure. |
| format | Article |
| id | doaj-art-bc97b88882204c8fa86e9f124fb8c574 |
| institution | Kabale University |
| issn | 2090-6412 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Cardiology |
| spelling | doaj-art-bc97b88882204c8fa86e9f124fb8c5742025-02-03T00:59:37ZengWileyCase Reports in Cardiology2090-64122022-01-01202210.1155/2022/5243594Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan ProcedureJun Muneuchi0Yuichiro Sugitani1Masaru Kobayashi2Hiroki Ezaki3Hiromu Yamada4Mamie Watanabe5Department of PediatricsDepartment of PediatricsDepartment of PediatricsDepartment of PediatricsDepartment of PediatricsDepartment of PediatricsSodium glucose cotransporter-2 (SGLT-2) inhibitors have been widespread in patients with heart failure; however, there is little information regarding its feasibility and safety among patients after the Fontan procedure. We presented five adults after the Fontan procedure who were treated with SGLT-2 inhibitors. All patients reduced oedema and/or pleural effusion despite other conjunct medications were ineffective. Although we did not measure the urine volume in all patients, all patients themselves reported an increase in urinary output after the administration of a SGLT-2 inhibitor. In addition, administration of a SGLT-2 inhibitor resulted in weight loss (4/5), an increase in systemic oxygen saturation (4/5), an increase in serum albumin level (4/5), an increase in estimated glomerular filtration ratio (4/5), and a decrease in plasma brain natriuretic peptide level (4/5). Our case series supported the feasibility and safety of SGLT-2 inhibitors in patients with Fontan circulatory failure, although the exact changes in urinary output were unknown in all patients. Further investigation will be required to explore a diuretic effect by SGLT-2 in patients after the Fontan procedure.http://dx.doi.org/10.1155/2022/5243594 |
| spellingShingle | Jun Muneuchi Yuichiro Sugitani Masaru Kobayashi Hiroki Ezaki Hiromu Yamada Mamie Watanabe Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure Case Reports in Cardiology |
| title | Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure |
| title_full | Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure |
| title_fullStr | Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure |
| title_full_unstemmed | Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure |
| title_short | Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure |
| title_sort | feasibility and safety of sodium glucose cotransporter 2 inhibitors in adults with heart failure after the fontan procedure |
| url | http://dx.doi.org/10.1155/2022/5243594 |
| work_keys_str_mv | AT junmuneuchi feasibilityandsafetyofsodiumglucosecotransporter2inhibitorsinadultswithheartfailureafterthefontanprocedure AT yuichirosugitani feasibilityandsafetyofsodiumglucosecotransporter2inhibitorsinadultswithheartfailureafterthefontanprocedure AT masarukobayashi feasibilityandsafetyofsodiumglucosecotransporter2inhibitorsinadultswithheartfailureafterthefontanprocedure AT hirokiezaki feasibilityandsafetyofsodiumglucosecotransporter2inhibitorsinadultswithheartfailureafterthefontanprocedure AT hiromuyamada feasibilityandsafetyofsodiumglucosecotransporter2inhibitorsinadultswithheartfailureafterthefontanprocedure AT mamiewatanabe feasibilityandsafetyofsodiumglucosecotransporter2inhibitorsinadultswithheartfailureafterthefontanprocedure |